Tuesday's Health Winners & Losers
TheStreet.com - USA
... The biopharmaceutical company reported positive phase I/II trial results on its multiple sclerosis treatment Tovaxin and has now begun a phase IIb trial of the ...

Opexa Therapeutics' (OPXA - commentary - Cramer's Take) shares jumped after the company released positive data from its clinical trials. The biopharmaceutical company reported positive phase I/II trial results on its multiple sclerosis treatment Tovaxin and has now begun a phase IIb trial of the drug. Shares were up 9.2% to $6.55.

---

Opexa Therapeutics shares on rise
Bizjournals.com - Charlotte,NC,USA
shares climbed by 6 percent Monday after the company posted positive clinical trial results of its multiple sclerosis treatment, Tovaxin. ...
See all stories on this topic